JP2019521098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521098A5 JP2019521098A5 JP2018562357A JP2018562357A JP2019521098A5 JP 2019521098 A5 JP2019521098 A5 JP 2019521098A5 JP 2018562357 A JP2018562357 A JP 2018562357A JP 2018562357 A JP2018562357 A JP 2018562357A JP 2019521098 A5 JP2019521098 A5 JP 2019521098A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- complementarity determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 92
- 102000036639 antigens Human genes 0.000 claims description 92
- 108091007433 antigens Proteins 0.000 claims description 92
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 19
- 102000047758 human TNFRSF18 Human genes 0.000 claims description 19
- 238000004873 anchoring Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000006052 T cell proliferation Effects 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims description 8
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 8
- 238000001516 cell proliferation assay Methods 0.000 claims description 8
- 239000003862 glucocorticoid Substances 0.000 claims description 8
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 8
- 102000000529 Costimulatory and Inhibitory T-Cell Receptors Human genes 0.000 claims description 7
- 108010041504 Costimulatory and Inhibitory T-Cell Receptors Proteins 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 5
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000005975 antitumor immune response Effects 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130091A JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348353P | 2016-06-10 | 2016-06-10 | |
| US62/348,353 | 2016-06-10 | ||
| US201662432023P | 2016-12-09 | 2016-12-09 | |
| US62/432,023 | 2016-12-09 | ||
| US201762500312P | 2017-05-02 | 2017-05-02 | |
| US62/500,312 | 2017-05-02 | ||
| PCT/US2017/036818 WO2017214548A1 (en) | 2016-06-10 | 2017-06-09 | Anti-gitr antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130091A Division JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521098A JP2019521098A (ja) | 2019-07-25 |
| JP2019521098A5 true JP2019521098A5 (OSRAM) | 2020-07-27 |
| JP7162535B2 JP7162535B2 (ja) | 2022-10-28 |
Family
ID=59078260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562357A Active JP7162535B2 (ja) | 2016-06-10 | 2017-06-09 | 抗ｇｉｔｒ抗体およびその使用 |
| JP2022130091A Pending JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130091A Pending JP2022159476A (ja) | 2016-06-10 | 2022-08-17 | 抗ｇｉｔｒ抗体およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10738126B2 (OSRAM) |
| EP (2) | EP3468999B1 (OSRAM) |
| JP (2) | JP7162535B2 (OSRAM) |
| KR (1) | KR102495601B1 (OSRAM) |
| CN (1) | CN109563170B (OSRAM) |
| AU (1) | AU2017278193B9 (OSRAM) |
| BR (1) | BR112018075434A2 (OSRAM) |
| CA (1) | CA3027121A1 (OSRAM) |
| CL (1) | CL2018003515A1 (OSRAM) |
| CO (1) | CO2018013298A2 (OSRAM) |
| IL (1) | IL263273B2 (OSRAM) |
| MA (1) | MA45233A (OSRAM) |
| MX (2) | MX2018015350A (OSRAM) |
| MY (1) | MY200162A (OSRAM) |
| PH (1) | PH12018502502A1 (OSRAM) |
| SG (1) | SG11201810525XA (OSRAM) |
| UA (1) | UA128687C2 (OSRAM) |
| WO (1) | WO2017214548A1 (OSRAM) |
| ZA (1) | ZA201807920B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| BR112018075434A2 (pt) | 2016-06-10 | 2019-03-19 | Regeneron Pharmaceuticals, Inc. | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| WO2018107178A1 (en) | 2016-12-09 | 2018-06-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods for sequencing t cell receptors and uses thereof |
| CR20200466A (es) * | 2018-03-13 | 2020-11-11 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020167919A1 (en) | 2019-02-12 | 2020-08-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| RU2734432C1 (ru) | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| US20230064703A1 (en) * | 2020-01-02 | 2023-03-02 | Nanjing GenScript Biotech Co., Ltd. | Anti-gitr antibodies and uses thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| AU2021232041A1 (en) | 2020-03-06 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
| WO2022148279A1 (zh) * | 2021-01-08 | 2022-07-14 | 苏州丁孚靶点生物技术有限公司 | 药物产品及其用途 |
| WO2022150654A2 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| KR102475255B1 (ko) * | 2021-05-10 | 2022-12-09 | 메디맵바이오 주식회사 | 항-gitr 항체 및 이의 용도 |
| AU2023235594A1 (en) | 2022-03-15 | 2024-09-12 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| ATE419357T1 (de) | 1997-11-18 | 2009-01-15 | Genentech Inc | Dna 19355 polypeptide, ein homolog des tumornekrosefaktors |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1462114A1 (en) | 2003-03-28 | 2004-09-29 | Universiteit Utrecht Holding B.V. | Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| MXPA05012475A (es) | 2003-05-23 | 2006-05-25 | Wyeth Corp | Anticuerpos y moleculas relacionadas con el ligando para el receptor tnf inducido por glucorticoides (gitr) y el ligando (gitr) y usos de los mismos. |
| US20060099171A1 (en) | 2004-11-05 | 2006-05-11 | Masahide Tone | Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| US20110212086A1 (en) | 2006-01-19 | 2011-09-01 | Genzyme Corporation | GITR Antibodies For The Treatment of Cancer |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도 |
| AR097306A1 (es) * | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PL3148579T3 (pl) | 2014-05-28 | 2021-07-19 | Agenus Inc. | Przeciwciała anty-gitr i sposoby ich zastosowania |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| AU2015338974B2 (en) * | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| BR112018075434A2 (pt) | 2016-06-10 | 2019-03-19 | Regeneron Pharmaceuticals, Inc. | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. |
-
2017
- 2017-06-09 BR BR112018075434-0A patent/BR112018075434A2/pt active Search and Examination
- 2017-06-09 MA MA045233A patent/MA45233A/fr unknown
- 2017-06-09 MX MX2018015350A patent/MX2018015350A/es unknown
- 2017-06-09 KR KR1020187036000A patent/KR102495601B1/ko active Active
- 2017-06-09 EP EP17731435.8A patent/EP3468999B1/en active Active
- 2017-06-09 CN CN201780048899.6A patent/CN109563170B/zh active Active
- 2017-06-09 IL IL263273A patent/IL263273B2/en unknown
- 2017-06-09 SG SG11201810525XA patent/SG11201810525XA/en unknown
- 2017-06-09 US US15/619,068 patent/US10738126B2/en active Active
- 2017-06-09 UA UAA201811485A patent/UA128687C2/uk unknown
- 2017-06-09 MY MYPI2018002044A patent/MY200162A/en unknown
- 2017-06-09 WO PCT/US2017/036818 patent/WO2017214548A1/en not_active Ceased
- 2017-06-09 CA CA3027121A patent/CA3027121A1/en active Pending
- 2017-06-09 AU AU2017278193A patent/AU2017278193B9/en active Active
- 2017-06-09 JP JP2018562357A patent/JP7162535B2/ja active Active
- 2017-06-09 EP EP23214299.2A patent/EP4344748A3/en not_active Withdrawn
-
2018
- 2018-11-22 ZA ZA2018/07920A patent/ZA201807920B/en unknown
- 2018-11-27 PH PH12018502502A patent/PH12018502502A1/en unknown
- 2018-12-07 CO CONC2018/0013298A patent/CO2018013298A2/es unknown
- 2018-12-07 CL CL2018003515A patent/CL2018003515A1/es unknown
- 2018-12-10 MX MX2022014695A patent/MX2022014695A/es unknown
-
2020
- 2020-06-26 US US16/913,963 patent/US11414494B2/en active Active
-
2022
- 2022-07-13 US US17/812,256 patent/US20230042324A1/en not_active Abandoned
- 2022-08-17 JP JP2022130091A patent/JP2022159476A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521098A5 (OSRAM) | ||
| JP6866294B2 (ja) | 抗ｐｄ−ｌ１抗体 | |
| JP6839772B2 (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP6701213B2 (ja) | 抗ｐｄ−１抗体 | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| WO2020102501A1 (en) | Anti-nkg2a antibodies and uses thereof | |
| JP2021531764A5 (OSRAM) | ||
| JP2019521645A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2017532037A5 (OSRAM) | ||
| JP2019500892A5 (OSRAM) | ||
| JP2020515247A5 (OSRAM) | ||
| AU2020283817A1 (en) | TIGIT and PD-1/TIGIT-binding molecules | |
| JP2019500891A5 (OSRAM) | ||
| JPWO2019246514A5 (OSRAM) | ||
| KR20160113272A (ko) | Tim-3에 대한 항체 분자 및 그의 용도 | |
| JP2018501197A5 (OSRAM) | ||
| IL299348B1 (en) | Antigen-binding proteins against human papillomavirus and methods of using them | |
| JP2018510617A5 (OSRAM) | ||
| CN112334488B (zh) | 靶向免疫检查点的双特异性抗体 | |
| WO2019030377A1 (en) | CD96 BINDING AGENTS AS IMMUNOMODULATORS | |
| JP2020504078A5 (OSRAM) | ||
| JP2019528046A5 (OSRAM) | ||
| JPWO2022061098A5 (OSRAM) | ||
| JP2023517794A (ja) | 抗ｔｎｆｒ２抗体及びその使用 |